Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of GMA102 added to metformin in adults with type 2 diabetes mellitus inadequately controlled on metformin
CTR20222558Phase 3Active
- Sponsor
- Gmax Biopharm
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of glutazumab in type 2 diabetes mellitus (T2DM), sponsored by Gmax Biopharm. Started Oct 2022; status: active.
02
Drugs
glutazumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20222558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222558.